Clinical Trial Update: Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Meglimine Sodium Succinate for correction of metabolic acidosis in critically ill patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Acidosis

Drugs mentioned

• Meglimine Sodium Succinate (Meglimine Sodium Succinate)

Snippet

Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company | Conditions: Metabolic Acidosis | Phase 2 | Status: COMPLETED